From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs"
BioProcessing Journal · 2026-07-28 · 3
DOI: 10.12665/j161.carson ↗At a glance
Journal article in BioProcessing Journal, published online on 2026-07-28. Written by Keith L. Carson.
Abstract (original language)
When I go to a therapeutic protein meeting, it’s very hard for me to hear these products referred to as “drugs.” But since they are being regulated by CDER, it’s a little easier to swallow. However, calling viral gene vectors and cellular therapies “drugs” is a bridge too far. My advice to my good friends at CBER is to keep calling their products “biologics,” or they may lose all of their regulatory responsibilities to CDER...
Cite
APA
Carson, K. L. (2026). From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs". BioProcessing Journal, 3. https://doi.org/10.12665/j161.carson
Vancouver
Carson KL. From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs". BioProcessing Journal. 2026:3. doi:10.12665/j161.carson
BibTeX
@article{Carson2026,
author = {Carson, Keith L.},
title = {From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs"},
journal = {BioProcessing Journal},
year = {2026},
pages = {3},
doi = {10.12665/j161.carson}
}
EUVIMED